July 2026 International Monthly Webinar
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Each month, NCODA’s International Monthly Webinar highlights timely topics, shared learning, and perspectives from across oncology care.
This month, we’ll discuss new clinical evidence from ASCO, strategies to improve access and outcomes for rural communities and veterans, the latest FDA approval for subcutaneous isatuximab-irfc in multiple myeloma, and updates from the NCODA Oncology Institute and Patient Education Sheets.
This Month’s Lineup:
Opening remarks from Tammy McClellan, PharmD (Riverside Healthcare).
Kelly Brunk, PharmD, BCOP (NCODA), shares the latest from NCODA’s Patient Education Sheets initiative, including updates and ongoing efforts to support oncology care teams.
Kristen Ray (NCODA) will shares the latest updates and announcements related to NCODA’s Oncology Institute.
Insights & Takeaways from ASCO – Douglas Braun, PharmD, CSP (NCODA), will share key takeaways from this year’s ASCO Annual Meeting and discuss new data and emerging trends that may impact oncology practice.
Strengthening Access and Outcomes in Rural Oncology – Barbara L. McAneny, MD (New Mexico Oncology Hematology Consultants, Ltd), explores the structural, clinical, and socioeconomic barriers to rural cancer care and discusses practical solutions that support patient-centered care closer to home.
Advancing the Care of Veterans with Advanced Prostate Cancer – Mathew Rettig, MD (David Geffen School of Medicine at UCLA | VA Greater Los Angeles), will discuss the evolving treatment landscape for advanced prostate cancer—including hormonal therapies, radioligand therapy, and targeted approaches—and share strategies to improve care coordination, expand treatment access, and support better outcomes within the VA healthcare system.
New FDA Approval: isatuximab-irfc (Sarclisa Escena™) Subcutaneous On-Body Injector – Hayley Reed, PharmD, BCACP (The American Oncology Network), breaks down the evidence supporting the new subcutaneous on-body injector for isatuximab-irfc and what oncology teams should know about incorporating it into multiple myeloma care.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
